Page 36 - Read Online
P. 36
Page 16 of 16 Moreno-Martínez et al. Rare Dis Orphan Drugs J 2024;3:9 https://dx.doi.org/10.20517/rdodj.2023.51
prevention, a review with meta-analysis. J Clin Neurosci 2019;65:83-6. DOI PubMed
124. Fellgiebel A, Gartenschläger M, Wildberger K, Scheurich A, Desnick RJ, Sims K. Enzyme replacement therapy stabilized white
matter lesion progression in Fabry disease. Cerebrovasc Dis 2014;38:448-56. DOI PubMed
125. Rost NS, Cloonan L, Kanakis AS, et al. Determinants of white matter hyperintensity burden in patients with Fabry disease. Neurology
2016;86:1880-6. DOI PubMed PMC
126. Lenders M, Karabul N, Duning T, et al. Thromboembolic events in Fabry disease and the impact of factor V Leiden. Neurology
2015;84:1009-16. DOI PubMed
127. Ferrari G, Reisin R, Kisinovsky I, et al. Major cardiovascular adverse events in Fabry disease patients receiving agalsidase alfa.
Medicina 2021;81:173-9. PubMed
128. Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system
involvement. Genet Med 2006;8:539-48. DOI PubMed
129. Fazekas F, Enzinger C, Schmidt R, et al; sifap1 Investigators. MRI in acute cerebral ischemia of the young: the Stroke in Young
Fabry Patients (sifap1) Study. Neurology 2013;81:1914-21. DOI PubMed
130. Politei JM. Can we use statins to prevent stroke in Fabry disease? J Inherit Metab Dis 2009;32:481-7. DOI PubMed
